{"url_path":"/sec/ganx/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1819411/0001104659-26-094041-index.html","accession_number":"0001104659-26-094041","cik":"0001819411","ticker":"GANX","issuer_name":"Gain Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819411/0001104659-26-094041-index.html","primary_entity_key":"0001819411","primary_entity_name":"Gain Therapeutics, Inc."},"word_count":142,"has_tables":true,"body_markdown":"**Item 2.02 Results of Operations and Financial Condition.**\n\nOn August 11, 2026, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026, and a business update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and exhibit be deemed incorporated by reference into any of the Company’s filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}